|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-4.24/-0.31
|
企业价值
39.64M
|
资产负债 |
每股账面净值
1.70
|
现金流量 |
现金流量率
--
|
损益表 |
收益
1.50M
|
每股收益
0.17
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/11/16 11:50 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. |